THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT
Saeed, J., Fathy, A., N., A., Al Azoni, O. (2013). THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT. EKB Journal Management System, 19(6), 1-6. doi: 10.21608/zumj.2013.4319
Jehan Saeed; Ayman Fathy; Ayman N.; Osama Al Azoni. "THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT". EKB Journal Management System, 19, 6, 2013, 1-6. doi: 10.21608/zumj.2013.4319
Saeed, J., Fathy, A., N., A., Al Azoni, O. (2013). 'THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT', EKB Journal Management System, 19(6), pp. 1-6. doi: 10.21608/zumj.2013.4319
Saeed, J., Fathy, A., N., A., Al Azoni, O. THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT. EKB Journal Management System, 2013; 19(6): 1-6. doi: 10.21608/zumj.2013.4319

THYROTOXIC PERIODIC PARALYSIS: DIAGNOSIS, MANAGEMENT AND ROLE OF PROPRANOLOL IN TREATMENT

Zagazig University Medical Journal
Article 4, Volume 19, Issue 6, November 2013, Page 1-6  XML PDF (684.03 K)
Document Type: Original Article
DOI: 10.21608/zumj.2013.4319
View on SCiNiTO View on SCiNiTO
Authors
Jehan Saeed1; Ayman Fathy1; Ayman N.1; Osama Al Azoni2
1Department of Internal Medicine
2Department of Neurology, Zagazig University
Abstract
Background: Hypokalemia is commonly encountered during paralysis in patients with thyrotoxic periodic paralysis (TPP) and may contribute to neuromuscular manifestations. This condition mainly affects male patients of Asian descent. With increasing population mobility and admixture, TPP as the presenting feature of hyperthyroidism is more common in Western countries and Gulf area. TPP is an alarming and potentially lethal complication of hyperthyroidism characterized by muscle paralysis and hypokalemia due to a massive intracellular shift of potassium. A potassium supplement has been recommended to hasten recovery and prevent cardiopulmonary complications. However, this recommendation has not yet proven efficacious. Hyperadrenergic activity has been implicated in the pathogenesis of TPP. We tested whether nonselective β-blockers could terminate neuromuscular symptoms rapidly while reducing an intracellular shift of potassium. Methods: We describe 7 patients who had an acute attack of TPP with characteristic hypokalemia. Results: After oral propranolol, 3 mg/kg, serum potassium concentrations increased promptly in all patients, and there was complete amelioration of paralysis. Only 3 patient needed short term K supplement for their sever hypokalemia and sever symptoms. No rebound hyperkalemia was detected. Conclusion: Given propranolol efficacy in this study, propranolol should be considered as a first-line therapy for TPP.
Keywords
Hypokalemia; TPP; Hyperthyroidism; Propranolol; periodic paralysis
Statistics
Article View: 251
PDF Download: 207